Am J Transplant, Volume 20, Suppl 3 Archives - Page 186 of 223 - ATC Abstracts

2020 American Transplant Congress
Comparison of Outcome Between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
S. Kim, M. Lim, J. Kwon, E. Jeong, J. Yang, K. Kim, K. Lee, O. Lee, J. Joh
Transplantation, Samsung Medical Center, Seoul, Korea, Republic of
*Purpose: For preventing immunological rejection after kidney transplantation, induction immunosuppressant agents such as basiliximab or rabbit anti-thymocyte globulin (r-ATG) are mostly used nowadays. We compared…
2020 American Transplant Congress
Clinical Significance of C4d and HLA-DSA on Post-Transplant Clinical Outcomes in Kidney Transplant Recipients with Antibody-Mediated Rejection
W. Park, O. Kwon, Y. Kim, J. Paek, K. Jin, S. Park, S. Han
Internal Medicine, Keimyung University School of Medicine, Keimyung University Kidney Institute, Daegu, Korea, Republic of
*Purpose: The clinicopathological diagnosis of rejection after kidney transplantation (KT) was well defined by Banff classification. In the diagnosis of antibody-mediated rejection (AMR), the presence…
2020 American Transplant Congress
Kidney Paired Donation in Brazil
J. Bastos¹, M. Mankowski², S. Gentry³, A. Massie⁴, C. Bisi¹, C. Duarte¹, V. Colares¹, D. Segev⁴, G. Ferreira¹
¹Transplant, Santa Casa de Misericordia de Juiz de Fora, Juiz de Fora, Brazil, ²King Abdullah University of Science and Technology, Thuwal, Saudi Arabia, ³US Naval Academy, Annapolis, MD, ⁴JHU, Baltimore, MD
*Purpose: It is estimated that up to 30% of potential living donor/recipient pairs are unable to proceed to living donor kidney transplantation (LDKT) for immunological…
2020 American Transplant Congress
Kidney Transplantation from Hepatitis C Infected Donors to Hepatitis C Negative Recipients: Does Organs Selection Matter?
B. Rawashdeh¹, L. Luu¹, Z. Sahli¹, E. McCracken¹, A. Doyle², K. Brayman¹, A. Agarwal¹
¹Transplant Surgery, University of Virginia, Charlottesville, VA, ²Division of Transplant Nephrology, University of Virginia, Charlottesville, VA
*Purpose: Recently, there has been a marked increase in the availability and use of kidneys from hepatitis C virus (HCV) positive deceased donors for transplantation.…
2020 American Transplant Congress
GLP1-RAs, SGLT2i Are Underutilized in Kidney Transplant Recipients with Diabetes Mellitus and Obesity
M. Stumpf, S. A. Dar, S. Rao, A. Doyle
University of Virginia, Charlottesville, VA
*Purpose: There is little research describing differences in use of antidiabetic medications amongst obese, diabetic patients with or without a history of kidney transplant. More…
2020 American Transplant Congress
How Prepared are Potential Donors to Donate?: Racial/Ethnic Differences in Potential Kidney Donors’ Knowledge and Education Before Starting Evaluation
A. Waterman¹, O. N. Ranasinghe¹, Y. Cui², J. L. Beaumont², D. Adey³, U. Reddy⁴, B. Campbell⁵, F. L. Weng⁶
¹Division of Nephrology, David Geffen School of Medicine, Los Angeles, CA, ²Terasaki Research Institute, Los Angeles, CA, ³Division of Nephrology, UCSF Health, San Francisco, CA, ⁴UC Irvine, Irvine, CA, ⁵Cedars Sinai Medical Center, Los Angeles, CA, ⁶St. Barnabas Medical Center, Livingston, NJ
*Purpose: Potential living donors of different races/ethnicities present for kidney donor evaluation with varying levels of knowledge.*Methods: We surveyed potential living donors about how they…
2020 American Transplant Congress
7-Years Retrospective Cohort of CNI to Belatacept Conversion
A. Morel¹, C. Dudreuilh¹, A. Moktefi², D. Kheav³, D. Mokrani¹, K. El Sakhawi¹, C. Champy⁴, P. Rémy¹, P. Grimbert¹, M. Matignon¹
¹Nephrology, APHP Henri Mondor, Créteil, France, ²Anatomopathology, APHP Henri Mondor, Créteil, France, ³Immunology, APHP Saint Louis, Paris, France, ⁴Urology, APHP Henri Mondor, Créteil, France
*Purpose: Analyze the long-term evolution after calcineurin inhibitors (CNIs) to Belatacept conversion in kidney allograft recipients.*Methods: In this single-center retrospective study, we collected all patients…
2020 American Transplant Congress
Safety and Efficacy of Endoscopic Transpapillary Gallbladder Stenting for Symptomatic Gallbladder Disease in Cirrhosis: A Systematic Review and Meta-Analysis
K. F. Haq¹, U. Iqbal², M. Khan³, F. Kamal⁴, S. Solanki⁵, R. Chakinala⁵, M. Siddiqui¹, M. Abu Ghanimeh¹, O. Sadiq¹, A. Watson¹, T. Zuchelli¹, R. Salgia¹
¹Gastroenterology & Hepatology, Henry Ford Hospital, Detroit, MI, ²Medicine, Geisinger Medical Center, Danville, PA, ³Gastroenterology & Hepatology, University of Alabama, Birmingham, AL, ⁴Gastroenterology & Hepatology, University of Tennessee, Knoxville, TN, ⁵Medicine, Guthrie Hospital, Sayre, PA
*Purpose: Endoscopic transpapillary gallbladder (cystic duct) stenting has been shown to be an effective treatment option for symptomatic gallbladder disease in patients with cirrhosis. However,…
2020 American Transplant Congress
Long Term Outcomes Following Uncontrolled and Controlled Donation after Cardiac Death Liver Transplantation in the United States
R. A. Choudhury¹, D. Yoeli¹, H. Yaffe¹, H. B. Moore¹, G. Hoeltzel², A. Schulick¹, K. D. Conzen¹, J. J. Pomposelli¹, E. A. Pomfret¹, T. L. Nydam¹
¹Department of Surgery- Division of Transplantation Surgery, University of Colorado Hospital, Aurora, CO, ²Thomas Jefferson University Hospital, Philadelphia, PA
*Purpose: Poor short-term outcomes following uncontrolled donation after cardiac death (uDCD) liver transplantation has led to near non-utilization of such donor allografts in the modern…
2020 American Transplant Congress
Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond UCSF Criteria: Tumor Biology Not the Tumor Number Decide the Long Term Outcome- A Single Center Retrospective Analysis of Using Extended Criteria
A. Thorat, L. Jeng, S. Hsu, H. Yang, P. Li, T. Chen, K. Poon
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan
*Purpose: HCC is the fifth most common cancer and the third most frequent cause of cancer deaths worldwide. After its introduction for LT in HCC…